

# Tim Meyer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7555518/publications.pdf>

Version: 2024-02-01

81  
papers

11,243  
citations

117625

34  
h-index

64796

79  
g-index

85  
all docs

85  
docs citations

85  
times ranked

12696  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. <i>British Journal of Cancer</i> , 2022, 126, 569-575.	6.4	10
2	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 38-47.	7.7	20
3	Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13096.	2.6	9
4	Novel Cellular Therapies for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 504.	3.7	14
5	A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS485-TPS485.	1.6	1
6	Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabemlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 434-434.	1.6	2
7	Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. <i>BMC Cancer</i> , 2022, 22, 377.	2.6	10
8	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. <i>Clinical Cancer Research</i> , 2022, 28, 3443-3451.	7.0	19
9	Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2657-2668.	7.0	4
10	Phase 0 study of vandetanib-eluting radiopaque embolics as a pre-operative embolization treatment in patients with resectable liver malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.5	0
11	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	7.3	235
12	Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 872-882.	3.6	12
13	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
14	Upregulation of C/EBP $\beta$ Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5961-5978.	7.0	47
15	Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. <i>British Journal of Cancer</i> , 2021, 125, 1350-1355.	6.4	15
16	Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 631-644.	3.1	8
17	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 293-313.	17.8	428
18	A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. <i>Hepatology Communications</i> , 2021, 5, 538-547.	4.3	6

#	ARTICLE	IF	CITATIONS
19	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	7.3	92
20	Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. <i>Liver International</i> , 2020, 40, 215-228.	3.9	27
21	Understanding the treatment algorithm of patients with metastatic pancreatic neuroendocrine neoplasms: A single-institution retrospective analysis comparing outcomes of chemotherapy, molecular targeted therapy and peptide receptor radionuclide therapy in 255 patients. <i>Neuroendocrinology</i> , 2020, 111, 863-875.	2.5	3
22	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020, 5, e000714.	4.5	51
23	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP- $\beta$ , in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3936-3946.	7.0	86
24	Stereotactic body radiotherapy for hepatocellular carcinoma – still searching for a role. <i>Journal of Hepatology</i> , 2020, 73, 15-16.	3.7	6
25	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). <i>BMI Open</i> , 2020, 10, e034527.	1.9	11
26	ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome. <i>Frontiers in Oncology</i> , 2020, 10, 971.	2.8	10
27	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 4795-4804.	7.0	58
28	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	3.7	165
29	Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4601-4601.	1.6	1
30	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2019, 154, 1038.	4.3	154
31	Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial). <i>Neuroendocrinology</i> , 2019, 108, 317-327.	2.5	16
32	Trial endpoints for systemic therapy in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 1060-1061.	3.7	1
33	Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. <i>British Journal of Cancer</i> , 2019, 120, 294-300.	6.4	25
34	Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4088-4088.	1.6	19
35	Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 305-305.	1.6	2
36	VERONa Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. <i>JMIR Research Protocols</i> , 2019, 8, e13696.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. World Journal of Gastroenterology, 2019, 25, 5991-6005.	3.3	43
38	Oncotherapies for HCC. , 2019, , 153-165.		0
39	Sorafenib and hepatic arterial infusion chemotherapy: another failed combination. The Lancet Gastroenterology and Hepatology, 2018, 3, 376-377.	8.1	4
40	Treatment of advanced hepatocellular carcinoma: beyond sorafenib. The Lancet Gastroenterology and Hepatology, 2018, 3, 218-220.	8.1	19
41	Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. Oncologist, 2018, 23, 766-e90.	3.7	59
42	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine, 2018, 379, 54-63.	27.0	1,677
43	Liquid Biopsies for Neuroendocrine Tumors: Circulating Tumor Cells, DNA, and MicroRNAs. Endocrinology and Metabolism Clinics of North America, 2018, 47, 471-483.	3.2	20
44	Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2018, 36, 4088-4088.	1.6	6
45	Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.. Journal of Clinical Oncology, 2018, 36, 475-475.	1.6	39
46	<sc>mRECIST</sc> to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase <sc>II</sc> trials comparing nintedanib vs sorafenib. Liver International, 2017, 37, 1047-1055.	3.9	58
47	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, The, 2017, 389, 1011-1024.	13.7	1,475
48	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. British Journal of Cancer, 2017, 116, 448-454.	6.4	66
49	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, The, 2017, 389, 2492-2502.	13.7	3,224
50	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 565-575.	8.1	362
51	mRECIST for systemic therapies: More evidence is required before recommendations can be made. Journal of Hepatology, 2017, 67, 195.	3.7	5
52	Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2017, 18, 1652-1664.	10.7	108
53	Nivolumab (nivo) in sorafenib (sor)-naïve and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. Journal of Clinical Oncology, 2017, 35, 4013-4013.	1.6	76
54	Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.. Journal of Clinical Oncology, 2017, 35, 226-226.	1.6	19

#	ARTICLE	IF	CITATIONS
55	A multicentre comparison between Child Pugh and Albuminâ€Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. <i>Liver International</i> , 2016, 36, 1821-1828.	3.9	85
56	Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. <i>British Journal of Cancer</i> , 2016, 115, 1540-1547.	6.4	33
57	Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2016, 23, 563-570.	3.1	24
58	Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours. <i>British Journal of Cancer</i> , 2016, 115, 1321-1327.	6.4	24
59	Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. <i>Clinical Cancer Research</i> , 2016, 22, 250-258.	7.0	149
60	Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. <i>Clinical Cancer Research</i> , 2016, 22, 79-85.	7.0	65
61	Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4078-4078.	1.6	30
62	Roles of miR-196a on gene regulation of neuroendocrine tumor cells. <i>Molecular and Cellular Endocrinology</i> , 2015, 412, 131-139.	3.2	12
63	Goblet cell appendiceal tumors â€“ Management dilemmas and long-term outcomes. <i>Surgical Oncology</i> , 2015, 24, 47-53.	1.6	41
64	Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2015, 22, L13-L18.	3.1	50
65	Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs. <i>PLoS ONE</i> , 2015, 10, e0125553.	2.5	37
66	Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. <i>Annals of Translational Medicine</i> , 2015, 3, 118.	1.7	14
67	Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 3069.	3.3	74
68	Capecitabine and streptozocinÂ±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Cancer</i> , 2014, 50, 902-911.	2.8	56
69	Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4150-TPS4150.	1.6	7
70	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. <i>Nature Genetics</i> , 2013, 45, 1483-1486.	21.4	275
71	Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 359-373.	2.4	24
72	Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2013, 31, 365-372.	1.6	148

#	ARTICLE	IF	CITATIONS
73	Status of hepatocellular cancer in Europe. Chinese Clinical Oncology, 2013, 2, 44.	1.2	2
74	Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Targeted Oncology, 2012, 7, 161-168.	3.6	22
75	EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. Journal of Hepatology, 2011, 55, 1309-1316.	3.7	286
76	Role of everolimus in pancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy, 2011, 11, 1653-1665.	2.4	10
77	Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors. Clinical Cancer Research, 2011, 17, 337-345.	7.0	99
78	Sarcoidosis and testicular cancer: A case series and literature review. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 350-354.	1.6	20
79	A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas. Clinical Cancer Research, 2009, 15, 4484-4492.	7.0	68
80	Imaging in targeted delivery of therapy to cancer. Targeted Oncology, 2009, 4, 201-217.	3.6	23
81	Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies. CardioVascular and Interventional Radiology, 2007, 30, 6-25.	2.0	698